Orexigen Therapeutics, Inc. (NASDAQ:OREX) and its partner Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) have filed a lawsuit against Actavis Plc (NYSE:ACT) to block a generic version of a weight-loss pill sold in the market under the name Contrave, according to Reuters.
Please to comment